Muscular Dystrophy Association Celebrates FDA Approval of Amicus Therapeutics’ Pombiliti + Opfolda for Treatment of Pompe Disease

Sep 28 2023 05:00

New York, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg...

Medicenna Announces Results of Annual and Special Meeting of Shareholders

Sep 28 2023 05:00

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today...

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Sep 28 2023 04:17

Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Sep 28 2023 04:15

Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

Sep 28 2023 04:15

Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave’s best-in-class GalNAc-siRNA capabilities and novel genetic insights from GSK

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

Sep 28 2023 04:11

AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms...

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Sep 28 2023 04:08

Provides Initial $59 Million and up to $168 Million Contingent on Milestones

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

Sep 28 2023 04:05

SAN DIEGO, California, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of five abstracts at the 2023 American College...

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

Sep 28 2023 04:02

BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the...

Madrigal Pharmaceuticals Announces Proposed Public Offering

Sep 28 2023 04:01

CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that it has commenced...

0/5 (0 Reviews)

Don't miss updates from Health Canada and FDA.

If you are looking for the latest regulatory updates or want the newest regulatory requirements guides, please leave your email and we'll keep you posted.